# Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

> **NCT04609540** · — · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 200 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04609540
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609540, "Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04609540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*